^
Association details:
Biomarker:MUC1 expression
Cancer:HER2 Positive Breast Cancer
Drug Class:MUC1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

A novel humanized MUC1 antibody–drug conjugate for the treatment of trastuzumab-resistant breast cancer

Published date:
09/29/2021
Excerpt:
...an antibody-drug conjugate (ADC) was generated by conjugating HzMUC1 with monomethyl auristatin (MMAE), and the efficacy of HzMUC1-MMAE on the MUC1-positive HER2+ breast cancer in vitro and in 'Xenograft' model was tested....Results from colony formation assay and flow cytometry demonstrated that HzMUC1-MMAE significantly inhibited cell growth by inducing G2/M cell cycle arrest and apoptosis in trastuzumab-resistant HER2-positive breast cancer cells.
DOI:
10.1093/abbs/gmab141